Skip to main content

Jose Miguel Lizcano De Vega

I am Professor (Full) of Biochemistry at UAB University. Since 2021, I lead the Laboratory of Protein Kinases and Cancer at VHIR. Our group investigates new cell signaling pathways that control the proliferation and survival of cancer cells. We collaborate with biopharmaceutical companies for the preclinical development of new anticancer drugs. We are interested in the role of the new MAP kinase ERK5 in cancer proliferation, and in modulation of autophagy and of stress of endoplasmic reticulum as new strategies to improve chemotherapy and immunotherapy treatments.

Institutions of which they are part

Head of group
Protein kinases in cancer research
Vall Hebron Institut de Recerca

Jose Miguel Lizcano De Vega

Institutions of which they are part

Head of group
Protein kinases in cancer research
Vall Hebron Institut de Recerca

I am Professor (Full) of Biochemistry at UAB University. Since 2021, I lead the Laboratory of Protein Kinases and Cancer at VHIR. Our group investigates new cell signaling pathways that control the proliferation and survival of cancer cells. We collaborate with biopharmaceutical companies for the preclinical development of new anticancer drugs. We are interested in the role of the new MAP kinase ERK5 in cancer proliferation, and in modulation of autophagy and of stress of endoplasmic reticulum as new strategies to improve chemotherapy and immunotherapy treatments.

I graduated in Biochemistry at the Universitat Autònoma de Barcelona (UAB). After obtaining a PhD in Biochemistry and Molecular Biology (Neurochemistry) at the UAB, I made a first postdoctoral stay at the Department of Biochemistry at Trinity College Dublin (1995-96), working on Molecular Pharmacology. In 1998, I joined the MRC Protein Phosphorylation Unit (Dundee, UK), where I specialized in the study of protein kinases and cellular signaling, and in their alteration in diseases such as diabetes and cancer.

In 2004, I joined the Institute of Neurosciences UAB as a Ramón y Cajal researcher. Since 2005, I am Associate Professor at the UAB Department of Biochemistry of the Faculty of Medicine. I founded the Cell Signaling group, which studies the role of protein kinases in degenerative processes such as neurodegenerative diseases and cancer. Since 2010, my interest has focused on the study of cell signaling alterations in cancer, and on the preclinical development of new antitumor drugs. I have been vice-director of the Department of Biochemistry and director of the Biochemistry Unit of the Faculty of Medicine of the UAB.

In 2021 I joined the VHIR Institute, to lead the Laboratory of Protein Kinases and Cancer, which I combine with my teaching activity on the UAB campus. The ultimate goal of my research is to understand the biochemical basis of the tumor cell, in order to develop new molecular therapies that improve the survival and quality of life of cancer patients.

Projects

Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders

IP: Lucas Moreno Martín-Retortillo
Collaborators: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, María de los Ángeles Rodríguez Sánchez, Uría Oficialdegui, Maria Luz, Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Elisabet Megías Roda, Raquel Hladun Alvaro, Ariadna Boloix Amenós, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia, Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Elena Andretta, Claire Diot, Amira Idrizovic
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00638
Duration: 01/01/2022 - 30/06/2025

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 0.01
Reference: RTC-2017-6261-1_LIZCANO
Duration: 01/10/2018 - 31/10/2021

Nuevas terapias anticancer basadas en la modulación de la MAP KINASA ERK5.

IP: Jose Miguel Lizcano De Vega
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: PID2019-107561RB-I00
Duration: 01/06/2020 - 18/10/2022

Ministerio de Ciencia

Related news

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

On World Cancer Research Day, we highlight the oncology research model of the Vall d'Hebron Campus that allows laboratory results to be transferred as quickly as possible to clinical practice.

Related professionals

Ana Lain Fernandez

Ana Lain Fernandez

Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Edgar Verdura Peralta

Edgar Verdura Peralta

Postdoctoral researcher
Pediatric Neurology
Read more
Estela Garcia Gea

Estela Garcia Gea

Research technician
Psychiatry, Mental Health and Addictions
Read more
Joan Roig Soriano

Joan Roig Soriano

Postdoctoral researcher
Gene Therapy at Nervous System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.